Chargement en cours...
Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis
Tyrosine kinase inhibitors (TKIs) were first approved for treating radioactive iodine-refractory differentiated thyroid cancer (DTC) and anaplastic thyroid cancer (ATC) 5 years ago. Among them, lenvatinib has a high response rate and has become the first-line drug for treating thyroid cancer. Althou...
Enregistré dans:
| Publié dans: | Mol Clin Oncol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
D.A. Spandidos
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7783723/ https://ncbi.nlm.nih.gov/pubmed/33414909 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2190 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|